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Background: In many cases of pancreatic adenocarcinoma (PDAC), the diagnosis
comes as a surprise to the patient, who often faces a disease that is already at an
advanced stage, with poor prognosis. The clinical visit during which the diagnosis is
communicated together with the first information regarding the planned treatments is of
paramount importance. We hypothesize that the clarity of such information can influence
patients’ engagement and thus their level of compliance.
Aims: This study aims to collect (a) quantitative data on the level of PDAC patient
engagement, (b) data on the rate of understanding of the information received from the
doctor, and (c) data on level of compliance; the possible associations between these
variables will be analyzed.
Methods: This is a single-center, observational, cross-sectional cohort study on
patients diagnosed with PDAC, approved by the Ethics Committee of the San Raffaele
Hospital. As no preliminary data are available on the association between PDAC
patients’ understanding rate and their level of engagement and of compliance, no power
calculation is possible. This is a pilot study, aimed at enrolling at least 45 PDAC patients
during a period of 3 months.
Conclusion: COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic
CAncer (COMMUNI. CARE) will be the first study specifically investigating whether there
is a relation between PDAC patients’ engagement, rate of understanding at the time of
diagnosis, and compliance.
Keywords: pancreatic cancer, communication, diagnosis, patient engagement, doctor–patient interaction,
therapeutic alliance, compliance
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INTRODUCTION
Background
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease
with a standardized incidence rate by age of 4.8 and a
standardized mortality rate of 4.4 per 100,000 persons worldwide
(1). During the last decades, the prognosis of most common
cancer types has dramatically improved, but this is not the
case of PDAC. Indeed, despite recent improvements, PDAC
5-years survival rate is only ∼8% (2). This is because the
majority of PDAC patients show unspecific symptoms, and the
diagnosis is usually made only at an advanced stage of the disease
(3). In addition, no population screening program is available
(4). More than 450,000 patients are diagnosed with PDAC
worldwide every year, with a significant burden for the health and
socioeconomic systems.
The diagnosis of PDAC inmost cases is completely unforeseen
by the patient, who faces the disease suddenly, often already at
an advanced stage, and without a progressive approach to it. The
clinical interview in which the diagnosis and the first information
regarding treatment options and prognosis are communicated,
therefore, is a key moment.
Doctor–patient communication is considered “time of care,”
as stated by the Italian law n.219/2017 (5). In light of that,
correct communication is an integral part of the care itself and
lays the foundations for the construction of the therapeutic
alliance between the treating physician and the patient, which is
essential to guarantee compliance with the proposed treatments.
There are, however, few studies conducted on doctor–patient
communication in cancer patients (6) and none specifically on
PDAC patients.
Many recent studies claim that a good level of patient
engagement is an essential condition to build a solid therapeutic
alliance (7, 8); in this regard, objective measurement scales
of the patient engagement level have been developed and
have been demonstrated to be useful tools to quantify the
patient’s involvement within the care process (9, 10). Among
them is the Patient Health Engagement Scale (PHE-S R©),
a recently validated assessment scale of simple and non-
invasive use, which requires only the administration of a
questionnaire (11).
Hypothesis
The hypothesis to be tested is that clarity of communication
between the treating physician and the patient at the time
of diagnosis, and the patient’s level of understanding of the
information received, influences a patient’s engagement and
compliance with the care process.
Aims
This study aims to (1) collect quantitative data about the level of
PDACpatients engagement and their rate of understanding of the
received information and (2) investigate the association between
engagement and rate of understanding and of these two variables
with the level of compliance.
METHODS AND ANALYSIS
Study Design
This will be a monocentric cohort study (observational, cross-
sectional) on PDAC patients.
Patients
Consecutive outpatients visited by three expert physicians at the
Gastroenterology, Pancreatic Surgery and Oncology Clinics of
the Pancreas Translational and Clinical Research Center, IRCCS
San Raffaele, Milan (Italy) will be considered includable if they
meet the following conditions:
a) adult patients (≥18 years)
b) of Italian mother tongue
c) have a histological diagnosis of PDAC obtained during the 4
weeks prior to the visit
d) the visit is their first visit, after completion of diagnostic
procedures and is the occasion in which diagnosis and/or
treatment strategies are communicated
e) give full, written, informed consent.
The following exclusion criteria will be applied:
a) PDAC recurrence after previous diagnosis and treatment
b) poor performance status [Eastern Cooperative Oncology
Group (ECOG) ≥ 3].
Variables
The following variables will be recorded in a dedicated Case
Report Form (CRF): age, sex, region of origin, educational
level of the patient, habits such as smoking and alcohol intake
as previously reported (12), date of the histological diagnosis
of pancreatic adenocarcinoma, its stage, and the proposed
treatment plan.
The level of patient engagement will be evaluated through the
PHE-s R© (see Appendix 1).
The rate of understanding of the information received
from the patient by the doctor will be determined during a
semistructured interview (see Appendix 2) by comparing the
number of information conveyed by the doctor with the number
of information received/correctly understood by the patient.
The compliance with treatments will be defined as the rate of
treatments received compared to what was proposed and planned
by the treating physicians and was considered possible by the
medical team in light of patient’s conditions and side effects.
Study Period
The enrolment is planned to start from June 2020 and will last
until the planned number of enrolled patients has been met.
Outcomes
The association between the level of engagement, as evaluated
by the PHE-s R©, and the patient’s rate of understanding during
the diagnostic interview, will be assessed to evaluate whether
the degree of clarity of the information provided by the doctor
influences the level of patient engagement.
The association between the level of patient engagement
is calculated with the PHE-s R© and patient’s estimated rate of
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understanding according to the interview and the adherence to
proposed treatments (compliance).
Description of the Intervention (Schedule
of Visits)
The study requires (i) the completion of the scheduled
outpatients visit with a gastroenterologist, surgeon, or oncologist
with strong expertise in PDAC, (ii) the filling of the PHE-
S R© questionnaire by the patient to investigate the level of
engagement, and (iii) the completion of a semistructured
interview to assess the rate of understanding of the information
received from the doctor.
In more detail:
i. The treating physician will inform the patient about the
study before starting the outpatient visit and communicating
information on PDAC diagnosis and planned treatments.
The treating physician will also ask permission to the
patient regarding the presence during the visit of an
external observer (a Ph.D. student in philosophy of language
and communication), who will take notes regarding the
information provided and will record the audio of the visit
if the patient gives further (optional) consent.
ii. After the visit, the external observer will ask the patient
further written informed consent to use the data collected
during the interview and to complete the study. Informed
consent forms are presented at this stage rather than at
a preliminary stage to avoid anticipating the diagnosis of
PDAC, which the patient might not have yet received from
the doctor.
iii. The patient will be asked to fill in the PHE-s R© questionnaire,
which takes ∼10min to be completed. PHE-s R© is a
standardized and validated tool to measure patients’
psychological readiness to engage in patients with different
medical disorders.
iv. The external observer will conduct a semistructured
interview of∼30min to ask the patient questions concerning
the clarity of the communication he had received from the
doctor and the type of language used, to record the rate of
understanding of the information. This phase will ideally take
place following the PHE-s R© questionnaire, but the patient
will be free to postpone it to another moment or day given
the possible difficulties for the patient to face an interview
immediately following the communication of the diagnosis.
The interview will be conducted by an expert observer in
the field of language and communication (a Ph.D. student in
philosophy of language and communication). The object of
the interview is the language used by the treating physician
and its clarity for the patient.
All patients will then be treated and followed up normally in the
context of the multidisciplinary team of the Pancreas Center that
also include the aid of “navigator” and “research” nurses.
The Medication of the Study
The study is observational, so a preplanned treatment is
not considered.
Statistical Analysis
Categorical variables will be compared using Fisher or chi-
square tests and continuous variables using t test or Mann–
Whitney tests, as appropriate. Subgroups with different levels
of engagement will be compared for variables such as sex, age,
education, geographic area, stage of disease, type of proposed
treatment, and other available data. The PHE-s R© questionnaire
provides continuous data. The possible correlation of the level
of engagement with the clarity of the received information
that will be considered as a categorical variable divided in
quartiles and with the compliance with treatments will be tested
by a Pearson test. Two different univariate and multivariate
logistic regression analyses will be run considering patient
engagement and compliance as outcome variables and patients’
and disease features and the clarity of communication as
explanatory variables.
The “enter” method will be employed including all variables
that had resulted to be significant at the univariate analysis. Tests
of statistical significance and confidence intervals will be two-
sided; a p < 0.05 will be considered to be statistically significant.
A dedicated software (Medcalc 12.1, Belgium) will be employed.
Power Size Calculation
There have been no previous studies on the association between
the patient’s understanding rate and the level of engagement and
the consequent level of compliance in patients with PDAC. This
is, therefore, a pilot study, and power size cannot be calculated.
Considering that at S. Raffaele Hospital, some 500 new PDAC
patients are seen per year, with the established inclusion criteria,
it is considered plausible that 45–60 patients will be enrolled in
3 months.
DISCUSSION
Active engagement of the patient to the therapeutic program
has been shown to be an important factor not only to obtain
improved compliance but also to improve the outcomes (13, 14).
Data on the communication between physicians and patients
with PDAC are scanty, and patients’ engagement has not been
systematically evaluated in this context (15).
We hypothesize that the clarity of communication between
the treating physician and the patient and the degree of
comprehension by the patient, especially during the first phases
of the cure, are associated with the level of engagement and
consequently with the compliance of patients with PDAC.
If the present pilot study will support this initial
hypothesis, further action to improve the clarity of the clinical
communication will be promoted.
ETHICS STATEMENT
The study was be performed under the Declaration of Helsinki
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was be obtained by the study collaborators. The results of
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